Viatris Inc. (VTRS)
USD 7.7
(1.65%)
USD 7.7
(1.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.51 Billion USD | -45.34% |
| 2022 | 6.43 Billion USD | 43.65% |
| 2021 | 4.47 Billion USD | 124.74% |
| 2020 | 1.98 Billion USD | -38.89% |
| 2019 | 3.26 Billion USD | -6.15% |
| 2018 | 3.47 Billion USD | 0.08% |
| 2017 | 3.47 Billion USD | 1.99% |
| 2016 | 3.4 Billion USD | 21.23% |
| 2015 | 2.8 Billion USD | 30.9% |
| 2014 | 2.14 Billion USD | 18.06% |
| 2013 | 1.81 Billion USD | 8.82% |
| 2012 | 1.66 Billion USD | 12.65% |
| 2011 | 1.48 Billion USD | 40.27% |
| 2010 | 1.05 Billion USD | 18.08% |
| 2009 | 894.88 Million USD | 21.84% |
| 2008 | 734.5 Million USD | 174.06% |
| 2007 | -991.8 Million USD | 0.0% |
| 2006 | - USD | 5.44% |
| 2005 | 352.71 Million USD | -1.3% |
| 2004 | 357.34 Million USD | -35.84% |
| 2003 | 556.93 Million USD | 0.0% |
| 2002 | - USD | 100.25% |
| 2001 | - USD | -11.48% |
| 2000 | - USD | 4.04% |
| 1999 | - USD | 238.14% |
| 1998 | - USD | 47.29% |
| 1997 | - USD | -36.06% |
| 1996 | - USD | -38.48% |
| 1995 | - USD | 235.82% |
| 1994 | - USD | -33.52% |
| 1993 | - USD | 629.17% |
| 1992 | - USD | 700.0% |
| 1991 | - USD | -92.04% |
| 1990 | - USD | -45.67% |
| 1989 | - USD | -45.12% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.03 Billion USD | 1857.14% |
| 2024 Q2 | 1.14 Billion USD | -52.17% |
| 2023 Q2 | 1.16 Billion USD | -3.03% |
| 2023 Q3 | 1.22 Billion USD | 5.13% |
| 2023 Q4 | -69.7 Million USD | -105.7% |
| 2023 Q1 | 1.19 Billion USD | 0.79% |
| 2023 FY | - USD | 37.31% |
| 2022 Q4 | 1.19 Billion USD | -18.04% |
| 2022 FY | - USD | 1044.98% |
| 2022 Q3 | 1.45 Billion USD | -1.14% |
| 2022 Q2 | 1.46 Billion USD | -8.17% |
| 2022 Q1 | 1.59 Billion USD | 26.26% |
| 2021 Q4 | 1.26 Billion USD | -27.19% |
| 2021 Q2 | 2 Billion USD | -6.6% |
| 2021 Q3 | 1.74 Billion USD | -12.99% |
| 2021 FY | - USD | -85.69% |
| 2021 Q1 | 2.14 Billion USD | 2123.68% |
| 2020 Q4 | 96.3 Million USD | -90.16% |
| 2020 Q1 | 744 Million USD | -21.96% |
| 2020 Q2 | 841.5 Million USD | 13.1% |
| 2020 Q3 | 978.4 Million USD | 16.27% |
| 2020 FY | - USD | 223.34% |
| 2019 FY | - USD | -17.81% |
| 2019 Q3 | 915.5 Million USD | 12.23% |
| 2019 Q4 | 953.4 Million USD | 4.14% |
| 2019 Q1 | 679.9 Million USD | -30.52% |
| 2019 Q2 | 815.7 Million USD | 19.97% |
| 2018 Q4 | 978.6 Million USD | 4.16% |
| 2018 Q1 | 703.4 Million USD | -39.39% |
| 2018 FY | - USD | -44.46% |
| 2018 Q2 | 822.8 Million USD | 16.97% |
| 2018 Q3 | 939.5 Million USD | 14.18% |
| 2017 Q2 | 876.9 Million USD | 13.41% |
| 2017 Q1 | 773.2 Million USD | -42.26% |
| 2017 FY | - USD | 14.05% |
| 2017 Q3 | 814 Million USD | -7.17% |
| 2017 Q4 | 1.16 Billion USD | 42.58% |
| 2016 Q2 | 755.5 Million USD | 48.78% |
| 2016 Q3 | 979.4 Million USD | 29.64% |
| 2016 Q4 | 1.33 Billion USD | 36.72% |
| 2016 FY | - USD | 7.91% |
| 2016 Q1 | 507.8 Million USD | -45.7% |
| 2015 Q3 | 900.3 Million USD | 51.92% |
| 2015 Q1 | 398 Million USD | -41.0% |
| 2015 FY | - USD | -14.62% |
| 2015 Q4 | 935.1 Million USD | 3.87% |
| 2015 Q2 | 592.6 Million USD | 48.89% |
| 2014 Q3 | 607.4 Million USD | 36.77% |
| 2014 Q2 | 444.1 Million USD | 2.97% |
| 2014 Q1 | 431.3 Million USD | -15.2% |
| 2014 Q4 | 674.6 Million USD | 11.06% |
| 2014 FY | - USD | -13.22% |
| 2013 Q3 | 496.8 Million USD | 0.0% |
| 2013 Q1 | - USD | -17.15% |
| 2013 Q4 | 508.6 Million USD | 2.38% |
| 2013 FY | - USD | 40.77% |
| 2013 Q2 | - USD | 94.69% |
| 2012 FY | - USD | -29.08% |
| 2012 Q4 | - USD | -48.26% |
| 2012 Q3 | - USD | 37.84% |
| 2012 Q2 | - USD | 49.16% |
| 2012 Q1 | - USD | -36.55% |
| 2011 Q1 | - USD | 11.05% |
| 2011 FY | - USD | 84.38% |
| 2011 Q2 | - USD | 14.88% |
| 2011 Q4 | - USD | -4.39% |
| 2011 Q3 | - USD | 0.41% |
| 2010 Q4 | - USD | 35.66% |
| 2010 Q1 | - USD | -28.44% |
| 2010 Q2 | - USD | 3.74% |
| 2010 Q3 | - USD | 14.07% |
| 2010 FY | - USD | 13.29% |
| 2009 Q3 | - USD | 0.85% |
| 2009 Q4 | - USD | 58.59% |
| 2009 Q1 | - USD | 34.29% |
| 2009 FY | - USD | 9.69% |
| 2009 Q2 | - USD | -23.43% |
| 2008 Q4 | - USD | -69.81% |
| 2008 Q3 | - USD | 218.98% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 50.26% |
| 2008 FY | - USD | 0.02% |
| 2007 Q3 | - USD | -119.28% |
| 2007 Q4 | - USD | 100.0% |
| 2007 FY | - USD | 108.06% |
| 2007 Q1 | - USD | 128.44% |
| 2007 Q2 | - USD | -15.19% |
| 2006 Q2 | - USD | 20.05% |
| 2006 FY | - USD | 5.44% |
| 2006 Q1 | - USD | 16.87% |
| 2006 Q3 | - USD | 15.09% |
| 2006 Q4 | - USD | -5.58% |
| 2005 Q2 | - USD | 26.95% |
| 2005 Q1 | - USD | 7.76% |
| 2005 FY | - USD | -35.09% |
| 2005 Q4 | - USD | 28.78% |
| 2005 Q3 | - USD | -14.78% |
| 2004 Q2 | - USD | 11.64% |
| 2004 Q3 | - USD | -25.35% |
| 2004 Q4 | - USD | -31.49% |
| 2004 FY | - USD | 10.2% |
| 2004 Q1 | - USD | -23.83% |
| 2003 Q2 | - USD | 2.27% |
| 2003 Q1 | - USD | 0.48% |
| 2003 Q4 | - USD | -5.23% |
| 2003 FY | - USD | 2.76% |
| 2003 Q3 | - USD | 22.23% |
| 2002 FY | - USD | 100.25% |
| 2002 Q4 | - USD | -3.02% |
| 2002 Q3 | - USD | 9.73% |
| 2002 Q2 | - USD | -19.59% |
| 2002 Q1 | - USD | 1.09% |
| 2001 Q4 | - USD | 16.02% |
| 2001 Q2 | - USD | 233.16% |
| 2001 Q1 | - USD | -190.86% |
| 2001 FY | - USD | -11.48% |
| 2001 Q3 | - USD | 81.84% |
| 2000 Q1 | - USD | -13.7% |
| 2000 Q4 | - USD | 26.01% |
| 2000 Q3 | - USD | -76.53% |
| 2000 Q2 | - USD | 212.19% |
| 2000 FY | - USD | 4.04% |
| 1999 FY | - USD | 238.14% |
| 1999 Q1 | - USD | -37.44% |
| 1999 Q2 | - USD | -0.97% |
| 1999 Q3 | - USD | 39.77% |
| 1999 Q4 | - USD | -13.25% |
| 1998 Q2 | - USD | 537.86% |
| 1998 FY | - USD | 47.29% |
| 1998 Q3 | - USD | 10.42% |
| 1998 Q4 | - USD | 66.27% |
| 1998 Q1 | - USD | -141.2% |
| 1997 Q1 | - USD | -8.67% |
| 1997 FY | - USD | -36.06% |
| 1997 Q4 | - USD | -33.69% |
| 1997 Q3 | - USD | 143.23% |
| 1997 Q2 | - USD | 13.14% |
| 1996 FY | - USD | -38.48% |
| 1996 Q2 | - USD | -36.46% |
| 1996 Q4 | - USD | 31.58% |
| 1996 Q3 | - USD | 86.89% |
| 1996 Q1 | - USD | -12.73% |
| 1995 Q1 | - USD | 21.03% |
| 1995 FY | - USD | 235.82% |
| 1995 Q2 | - USD | -7.32% |
| 1995 Q4 | - USD | -47.62% |
| 1995 Q3 | - USD | -30.92% |
| 1994 Q4 | - USD | -7.51% |
| 1994 Q1 | - USD | 95.65% |
| 1994 Q3 | - USD | 4.27% |
| 1994 Q2 | - USD | 108.15% |
| 1994 FY | - USD | -33.52% |
| 1993 Q3 | - USD | -39.8% |
| 1993 Q4 | - USD | 16.95% |
| 1993 FY | - USD | 629.17% |
| 1993 Q1 | - USD | 4.12% |
| 1993 Q2 | - USD | -44.63% |
| 1992 Q3 | - USD | 210.17% |
| 1992 Q1 | - USD | 323.08% |
| 1992 FY | - USD | 700.0% |
| 1992 Q2 | - USD | 7.27% |
| 1992 Q4 | - USD | -7.1% |
| 1991 Q3 | - USD | 350.0% |
| 1991 Q1 | - USD | -700.0% |
| 1991 Q4 | - USD | 160.0% |
| 1991 FY | - USD | -92.04% |
| 1991 Q2 | - USD | 66.67% |
| 1990 Q2 | - USD | -62.07% |
| 1990 FY | - USD | -45.67% |
| 1990 Q4 | - USD | 112.5% |
| 1990 Q1 | - USD | 2033.33% |
| 1990 Q3 | - USD | -136.36% |
| 1989 Q2 | - USD | 107.3% |
| 1989 FY | - USD | -45.12% |
| 1989 Q1 | - USD | -303.6% |
| 1989 Q4 | - USD | -112.0% |
| 1989 Q3 | - USD | -24.24% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alvotech | -484.86 Million USD | 825.258% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | -1040.506% |
| Journey Medical Corporation | 1.92 Million USD | -182955.7% |
| Dynavax Technologies Corporation | 9.66 Million USD | -36280.095% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 2313.682% |
| PainReform Ltd. | -9.56 Million USD | 36848.877% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 92048.631% |
| SCYNEXIS, Inc. | 73.47 Million USD | -4685.721% |
| Silver Spike Investment Corp. | 7.34 Million USD | -47808.001% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 92048.631% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 2442.647% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -297404.23% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | -3116.703% |
| Alpha Teknova, Inc. | -25.53 Million USD | 13869.137% |
| Embecta Corp. | 245.4 Million USD | -1332.967% |
| Safety Shot Inc | -12.18 Million USD | 28958.817% |
| Procaps Group, S.A. | 104.02 Million USD | -3280.372% |
| Cosmos Health Inc. | -17.06 Million USD | 20710.373% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 149674.013% |
| Pacira BioSciences, Inc. | 162.89 Million USD | -2058.726% |
| Theratechnologies Inc. | -10.31 Million USD | 34198.409% |
| Harrow Health, Inc. | 9.72 Million USD | -36066.821% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 77812.707% |
| Biofrontera Inc. | -18.45 Million USD | 19156.522% |
| DURECT Corporation | -24.68 Million USD | 14346.07% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -3478.698% |
| Cronos Group Inc. | -72.14 Million USD | 4973.941% |
| OptiNose, Inc. | -15.55 Million USD | 22709.786% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 480.218% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 9845.857% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -13287.958% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -9659.651% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 89752.795% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 494789.456% |
| Radius Health, Inc. | 38.31 Million USD | -9079.066% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 109475.569% |
| ProPhase Labs, Inc. | -14.82 Million USD | 23816.868% |
| Phibro Animal Health Corporation | 84.6 Million USD | -4056.275% |
| Procaps Group S.A. | 104.02 Million USD | -3280.372% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 41958.112% |
| Rockwell Medical, Inc. | -4.69 Million USD | 75014.785% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 347580.237% |
| SIGA Technologies, Inc. | 84.15 Million USD | -4078.378% |
| Tilray Brands, Inc. | -72.84 Million USD | 4927.506% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -432966.502% |
| Shineco, Inc. | -26.55 Million USD | 13342.869% |
| PetIQ, Inc. | 81.48 Million USD | -4215.465% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 97304.577% |
| Incannex Healthcare Limited | -18.5 Million USD | 19103.999% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -745.109% |
| Alimera Sciences, Inc. | 7.27 Million USD | -48230.126% |
| Assertio Holdings, Inc. | -222.44 Million USD | 1680.826% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 88218.499% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 83590.211% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 21026.565% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 17655.481% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 2458.089% |
| Hempacco Co., Inc. | -12.77 Million USD | 27630.149% |
| Talphera, Inc. | -9.84 Million USD | 35829.527% |
| Alvotech | -484.86 Million USD | 825.258% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | -4437.302% |
| Lantheus Holdings, Inc. | 491 Million USD | -616.184% |
| Currenc Group, Inc. | -1.9 Million USD | 185123.051% |
| Kamada Ltd. | 21.53 Million USD | -16229.99% |
| Indivior PLC | 66 Million USD | -5228.03% |
| Evoke Pharma, Inc. | -7.29 Million USD | 48322.13% |
| Flora Growth Corp. | -45.87 Million USD | 7766.231% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 17655.481% |
| Evolus, Inc. | -41.81 Million USD | 8510.667% |
| HUTCHMED (China) Limited | 25.52 Million USD | -13675.071% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | -1356.325% |
| Akanda Corp. | -27.73 Million USD | 12778.612% |